A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
In the register
The register attaches this trial to Rezpegaldesleukin (REZPEG) (Nektar Therapeutics), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Nektar Therapeutics
- Participants (registry)
- 94
- Start
- April 2024
- Primary completion
- November 2025
- Study completion
- August 2026
- Last registry update
- September 2026
- Countries
- United States, Canada, Poland
Conditions studied: Alopecia Areata
Interventions: Rezpegaldesleukin, REZPEG, NKTR-358, LY3471851 (formerly), Placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.